The EPS projection of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for period quarter completed 2016-12-31 is $-0.76.
The EPS estimates pronounced a week and 30 days ago were $-0.76 and $-0.76 correspondingly. The EPS forecasts specified 60 and 90 days before were $-0.76 and $-0.76 respectively. From a week ago, the aberration in EPS forecast is 0 percent.
The mean EPS prediction straightaway before the earnings release for the quarter completed 2 is $-0.76 based on 4 EPS estimations. The EPS stated on 2016-08-09 was $-0.91. The EPS surprise was $-0.17, or -22.97 percent. The standard deviation as per known EPS estimates was $0.23.
The positive EPS revisions were 0 a week earlier and negative revisions were 0. In last 30 and 60 days, the positive EPS revisions were 0 and 0 correspondingly, while for 90 and 120 days, revisions count was 0 and 0.
The negative revisions of per-share earnings in the last 30 and 60-days were 0 and 3 in that order. however, for 90 and 120 days’ period, the count was 3 and 3 in that order.
EPS revisions upgrade and downgrade in the last 18 days were 0 and 4 correspondingly.
Quarterly Sales Estimates
The arithmetic mean of probable annual sales of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) is $7.29 and the median was $7.52. The estimate is stated by 3 analysts for the fiscal 2016.
The highest annual projection is $9.45 and lowest sales target is $4.9. This marks a standard deviation of $2.283.
Almost 3 have given revised positive sales forecast in the past week and 3 have downgraded forecasts. As per the stated estimates, the change in target from the past week is 0 percent.
Nearly 3 have revised sales projections in positive side over the past month and 3 have downgraded forecasts. This shows a mean estimate deviation of 1.602 percent.
Just about 3 have revised sales forecast on plus side over the quarter and 3 have downgraded forecasts. This shows mean estimate deviation of 1.602 percent.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...